Michael DiFiore
Stock Analyst at Evercore ISI
(0.84)
# 3,868
Out of 4,579 analysts
9
Total ratings
55.6%
Success rate
-8.4%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Michael DiFiore
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| MDGL Madrigal Pharmaceuticals | Maintained: Buy | $392 → $649 | $551.25 | +17.73% | 2 | May 7, 2026 | |
| VTVT vTv Therapeutics | Initiated Coverage: Buy | $44 | $31.02 | +41.84% | 1 | Mar 12, 2026 | |
| ALT Altimmune | Initiated Coverage: Buy | $25 | $2.96 | +744.59% | 1 | Aug 22, 2025 | |
| SKYE Skye Bioscience | Initiated Coverage: Buy | $10 | $0.6228 | +1,505.65% | 1 | Aug 15, 2025 | |
| HALO Halozyme Therapeutics | Reiterated: Buy | $55 | $81.48 | n/a | 2 | May 15, 2025 | |
| ATRA Atara Biotherapeutics | Downgraded: Hold | n/a | $7.71 | n/a | 1 | Nov 9, 2023 | |
| CLYM Climb Bio | Initiated Coverage: Buy | n/a | $12.79 | n/a | 1 | Sep 8, 2021 |
Madrigal Pharmaceuticals
May 7, 2026
Maintained: Buy
Price Target: $392 → $649
Current: $551.25
Upside: +17.73%
vTv Therapeutics
Mar 12, 2026
Initiated Coverage: Buy
Price Target: $44
Current: $31.02
Upside: +41.84%
Altimmune
Aug 22, 2025
Initiated Coverage: Buy
Price Target: $25
Current: $2.96
Upside: +744.59%
Skye Bioscience
Aug 15, 2025
Initiated Coverage: Buy
Price Target: $10
Current: $0.6228
Upside: +1,505.65%
Halozyme Therapeutics
May 15, 2025
Reiterated: Buy
Price Target: $55
Current: $81.48
Upside: n/a
Atara Biotherapeutics
Nov 9, 2023
Downgraded: Hold
Price Target: n/a
Current: $7.71
Upside: n/a
Climb Bio
Sep 8, 2021
Initiated Coverage: Buy
Price Target: n/a
Current: $12.79
Upside: n/a